Mark Stenhouse has been appointed as the President of Exact Sciences Corp. Mark brings over 30 years of experience to the position, and is expected to continue the success of Exact Science’s flagship product, Cologuard.
MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients
MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: Brussels MDXH.BR), an international healthcare company, developing and offering molecular diagnostic tests to personalize the diagnosis and treatment of urologic cancer, today announced promising research results with a new liquid biopsy test in development. Data from this study, published in The Prostate, January 12, 2018 indicate that the...
Patient care is put to the test as clinical laboratory services are hit with a one-two punch in rate cuts
The CMS data collection process, while attempting to adhere to the 2014 PAMA statute, falls short of the expectations of the clinical laboratory industry. In order to fix these issues with data collection and improve lab payment rates, Congress must pass additional legislation.
Companies such as Danaher, Agilent, and DiaSorin presented at the JP Morgan Healthcare Conference. The companies shared areas of potential growth and strategy in the coming year.
The United States is moving towards value-based payments for populations, and precision medicine for individuals. With the use of an appropriateness modifier, the fee could be increased in high-value situations, and decreased in low-value situations.
The US Centers for Medicare & Medicaid Services on Friday reined in a national coverage proposal for next-generation sequencing oncology panels that had the lab industry worried that they'd have to successfully take their tests through US Food and Drug Administration's review if they hoped to secure Medicare coverage and had cancer patients vexed that the government payor was limiting their...
FDA Commissioner Scott Gottlieb urges insurers to encourage biosimilar competition. This is part of an effort to ultimately create better savings for patients.
The US Centers for Medicare & Medicaid Services has approved CureOne's N1 Registry as a repository to which doctors can submit data and show that they are meeting quality metrics around cancer biomarker testing tied to payment.
- 1 of 400
- next ›